Multiple determinants of antimetabolite action in humans.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000378:metabolism* / Q000627:therapeutic use; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001086:Arabinofuranosyluracil / Q000097:blood; D003561:Cytarabine / Q000378:metabolism / Q000627:therapeutic use; D004247:DNA / Q000378:metabolism; D003630:Daunorubicin / Q000627:therapeutic use; D003641:Deamination; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D001086:Arabinofuranosyluracil; D004317:Doxorubicin; D004247:DNA; D003630:Daunorubicin